Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Takeda Licenses ImmunoGen’s ADC Technology | Contract Pharma

What are you searching for?

Sign in
Breaking News

Takeda Licenses ImmunoGen’s ADC Technology

To develop targeted anticancer therapeutics for as many as two undisclosed targets

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Takeda Pharmaceutical Co. has licensed exclusive rights to use ImmunoGen’s ADC technology to develop and commercialize targeted anticancer therapeutics for as many as two undisclosed targets. Takeda has the option to take a license for a third target for an additional upfront fee.
 
ImmunoGen will receive $20 million upfront, and for each target, is eligible to receive milestone payments of as much as $210 million plus royalties on sales of any resulting ADC products. Takeda is responsible for the development, manufacturing and marketing of any resulting ADC products.
 
“Takeda shares our commitment to developing novel anticancer therapies that meaningfully improve the lives of patients, and we look forward to collaborating with them to create important new ADC product candidates,” said Daniel Junius, ImmunoGen president and chief executive officer.
 
“ADC technology is a critically important tool in addressing unmet needs in oncology,” said Christopher Claiborne, Ph.D., Head of the Oncology Drug Discovery Unit at Takeda. “By partnering with ImmunoGen, we are able to leverage this important technology in Takeda’s R&D program and bring novel agents through the clinic.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics